Raymond James & Associates Intercept Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$15.46 - $24.5 $424,145 - $672,157	-27,435 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$19.33 - $37.75 $329,209 - $642,920	17,031 Added 163.7%	27,435 $633,000
Q4 2020 Feb 12, 2021	BUY	$24.48 - $42.47 $254,689 - $441,857	10,404 New	10,404 $257,000
Q3 2020 Nov 04, 2020	SELL	$39.09 - $53.44 $2.53 Million - $3.46 Million	-64,829 Closed	0 $0
Q2 2020 Jul 28, 2020	SELL	$46.7 - $92.04 $2.05 Million - $4.05 Million	-43,992 Reduced 40.43%	64,829 $3.11 Million

Q1 2020 Apr 21, 2020	SELL	$48.35 - $118.68 $751,504 - $1.84 Million	-15,543 Reduced 12.5%	108,821 $6.85 Million
Q4 2019 Feb 12, 2020	BUY	$57.36 - $124.1 $941,851 - $2.04 Million	16,420 Added 15.21%	124,364 $15.4 Million
Q3 2019 Nov 07, 2019	BUY	$58.69 - $80.46 $1.18 Million - $1.62 Million	20,095 Added 22.87%	107,944 $7.16 Million
Q2 2019 Aug 06, 2019	BUY	$77.77 - $120.68 $1.17 Million - $1.81 Million	15,019 Added 20.62%	87,849 $6.99 Million
Q1 2019 May 06, 2019	SELL	$91.83 - $120.68 $1.46 Million - $1.92 Million	-15,931 Reduced 17.95%	72,830 $8.15 Million
Q4 2018 Feb 11, 2019	BUY	$85.79 - $126.46 $905,084 - $1.33 Million	10,550 Added 13.49%	88,761 $8.95 Million
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $23,449 - $33,800	-265 Reduced 0.34%	78,211 $9.88 Million
Q2 2018 Aug 14, 2018	BUY	$60.0 - $85.67 $19,440 - $27,757	324 Added 0.41%	78,476 $6.59 Million
Q1 2018 May 14, 2018	BUY	$52.72 - $67.25 $2.32 Million - $2.96 Million	44,079 Added 129.37%	78,152 $4.81 Million
Q4 2017 Feb 14, 2018	BUY	$58.2 - $72.76 $1.98 Million - $2.48 Million	34,073	34,073 $1.99 Million

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account